HBA-14
New service: HBA-14™
The 14-Day Pharma CAPEX Feasibility Sprint
A 14-day owner-side feasibility sprint for early GMP manufacturing investment decisions
HBA-14™ delivers a Feasibility Study and an owner-side Business Case on one coherent basis - capacity, classified area, GMP/CQV, regulatory pathway, schedule, TPC, investment logic and risk - before the next engineering commitment is made.
The 14-Day Pharma CAPEX Feasibility Sprint
A 14-day owner-side feasibility sprint for early pharmaceutical CAPEX decisions.
It delivers a Feasibility Study and an owner-side Business Case on one coherent basis - before the next engineering commitment is made.
The problem
Early pharma CAPEX feasibility often fails before engineering really starts.
Technical scope, cost, GMP/CQV, regulatory timing, schedule and the business
case are often built on different assumptions and reconciled too late.
HBA-14™ creates one coherent decision basis before the next capital commitment.
What the 14 days produce
- Feasibility Study Report
- Owner-side Business Case
- Capacity and bottleneck logic
- Classified area and GMP-grade / functional-zone model
- AACE Class 5 TPC basis and Level 1 schedule
- GMP/CQV and regulatory-pathway assumptions
- RA-gated first-sale logic
- Risk register and owner-side recommendation
Clear boundary
HBA-14™ is not detailed engineering, not a procurement basis, not a regulatory
submission and not construction-ready design.
It is Gate 1 decision support - the front-end capital direction layer.Executive Program Director with over 20 years of global experience managing multi-million-dollar CAPEX portfolios, greenfield expansions, and complex technology transfers within the highly regulated pharmaceutical sector.
